OSLO, Norway, Sept. 15, 2021 /PRNewswire/ -- Photocure ASA
(OSE: PHO), the Bladder Cancer Company, announces a clinical data
presentation and highlights from the 2021 American Urological
Association Annual Congress (AUA2021), which was held virtually
September 10-13, 2021. During the
program, new results from a study using Blue Light Cystoscopy
(BLC®) with Cysview® in the surveillance
setting were reported in a podium presentation, and separately, BLC
with Cysview was discussed in an Expert Presentation on Surgical
Techniques.
The American Urological Association (AUA) meeting is one of
largest international meetings in the urology calendar. This year's
event included an innovative, evidence-based, quality program
for urologists and urologic health care professionals
worldwide.
Podium Presentation
Title: UTILITY OF BLUE LIGHT FLEXIBLE CYSTOSCOPY FOR
BLADDER CANCER SURVEILLANCE AFTER INTRAVESICAL THERAPY
Presenter: Sanam Ladi Seyedian, M.D., University of Southern California
Session and Date: PD-63: Bladder: Cancer
Non-Invasive III: Sept. 13, 2021
Results were provided by two high-volume treatment
facilities that perform Blue Light Flexible Cystoscopy (BLFC)
and are participants in the Blue Light Cystoscopy with Cysview
Registry. In this study, data was captured from 277 office
based BLFC examinations in 136 patients who received intravesical
BCG or chemotherapy, as part of standard of care treatment for
non-muscle invasive bladder cancer (NMIBC).
From these examinations, a total of 52 office-based
biopsies were taken, of which 23 (44%) were confirmed as malignant.
BLFC identified all 23 malignancies, demonstrating 100% sensitivity
for cancer detection in this cohort, whereas analysis by cytology
identified only 3 of the 23 confirmed malignancies. Additionally,
from the 277 total examinations, 23 (8%) were White Light
Cystoscopy (WLC) normal and BLFC abnormal. Of these 23 discordant
results, 16 had office-based biopsies and cancer was confirmed in 9
cases (56%), which would have been missed by WLC alone.
The study authors concluded that office-based BLFC helps improve
early detection of recurrence in cases with normal WLC and can aid
in surveillance of patients receiving intravesical therapy, enhance
performance of office-based biopsy and increase early detection of
BCG unresponsive disease.
"The results from this study show that use of Blue Light
Cystoscopy with Cysview for patient surveillance improved the
ability to detect recurrent disease in this high-risk,
recently-treated patient cohort, which can significantly impact
future treatment decisions," said Dr. Sia Daneshmand, one of the study
authors. "Early detection of recurrent or residual cancer
during initial treatment is essential for properly risk-stratifying
all bladder cancer patients, and confirming response to treatment
on follow-up and can have a major impact on subsequent treatment
pathways and patient outcomes. As a result, Blue Light Cystoscopy
can be an important tool throughout the continuum of care for
patients diagnosed with bladder cancer."
Dr. Sia Daneshmand, M.D., is
a Professor of Urology with Clinical Scholar designation and
serves as director of clinical research as well as the urologic
oncology (SUO) fellowship director at the University of Southern California (USC) in Los
Angeles.
Abstract Link:
https://www.auajournals.org/doi/abs/10.1097/JU.0000000000002107.03
Expert Presentation
Title: ADVANCES IN ENDOSCOPIC TREATMENT OF BLADDER
TUMORS
Presenter: Yair Lotan, M.D., UT Southwestern Medical
Center
Session and Date: Plenary Session: Surgical
Techniques: Sept. 10, 2021
In this presentation, Dr. Lotan emphasized the importance of BLC
with Cysview in accurately detecting NMIBC, stratifying bladder
tumors, and helping to perform a complete TURBT in the operating
room. He also provided an expert perspective on how biopsy and
fulguration in the surveillance setting can positively impact
patient outcomes using BLC with Cysview in the office-based
setting.
Dr. Lotan is a Professor of the Department of Urology at UT
Southwestern and Jane and John Justin Distinguished Chair in
Urology, In Honor of Claus G.
Roehrborn, M.D. He is Vice chair of Clinical Affairs and
chief of urologic oncology.
"The study results presented at this year's AUA meeting as
well as the discussion on BLC in the Surgical Techniques
presentation underscores how critically important it is for
patients to receive the proper bladder cancer care whether they are
having tumor resection in the hospital or follow-up
procedures" said Geoffrey
Coy, Vice President and General Manager of North American
Operations at Photocure. "These new study results also
highlight the range of opportunities made possible by Blue Light
Cystoscopy for urologists, and the benefits to patients, especially
when including flexible Blue Light Cystoscopy in the office setting
as part of the continuum of care. We remain focused on expanding
the availability of the procedure so that more physicians and
patients have access to this important
solution."
Note to editors: All trademarks mentioned in this
release are protected by law and are registered trademarks of
Photocure ASA
About Bladder Cancer
Bladder cancer ranks as the seventh most common cancer worldwide
with 1 720 000 prevalent cases (5-year prevalence
rate)1a, 573 000 new cases and more than
200 000 deaths annually in 2020.1b
Approx. 75% of all bladder cancer cases occur in
men.1 It has a high recurrence rate with an average of
61% in year one and 78% over five years.2 Bladder cancer
has the highest lifetime treatment costs per patient of all
cancers.3
Bladder cancer is a costly, potentially progressive disease for
which patients have to undergo multiple cystoscopies due to the
high risk of recurrence. There is an urgent need to improve both
the diagnosis and the management of bladder cancer for the benefit
of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive
bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC),
depending on the depth of invasion in the bladder wall. NMIBC
remains in the inner layer of cells lining the bladder. These
cancers are the most common (75%) of all BC cases and include the
subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the
cancer has grown into deeper layers of the bladder wall. These
cancers, including subtypes T2, T3, and T4, are more likely to
spread and are harder to treat.4
1 Globocan. a) 5-year prevalence / b)
incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [April 2021].
2 Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
3 Sievert KD et al. World J Urol
2009;27:295–300
4 Bladder Cancer. American Cancer
Society. https://www.cancer.org/cancer/bladder-cancer.html
About
Hexvix®/Cysview® (hexaminolevulinate
HCl)
Hexvix/Cysview is a drug that preferentially accumulates in
cancer cells in the bladder making them glow bright pink during
Blue Light Cystoscopy (BLC®). BLC with
Hexvix/Cysview improves the detection of tumors and leads to
more complete resection, fewer residual tumors and better
management decisions.
Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all other
markets. Photocure is commercializing Cysview/Hexvix directly in
the U.S. and Europe and has
strategic partnerships for the commercialization of Hexvix/Cysview
in China, Canada, Chile, Australia, and New
Zealand. Please refer to
https://photocure.com/partnering-with-photocure/our-partners/ for
further information on our commercial partners.
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative
solutions to improve the lives of bladder cancer patients. Our
unique technology, making cancer cells glow bright pink, has led to
better health outcomes for patients worldwide. Photocure is
headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange (OSE: PHO). For more information,
please visit us at www.photocure.com, www.hexvix.com,
www.cysview.com.
For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com
Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com
David Moskowitz
Head of Investor Relations
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/photocure/r/presentations-of-blue-light-flexible-cystoscopy-study-results-and-bladder-cancer-surgical-techniques,c3414940
The following files are available for download:
|
https://mb.cision.com/Main/17498/3414940/1468204.pdf
|
Release
|